|
Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
DelSite
Biotechnologies, Inc.
(OTC: DSII)
Digital
Angel Corporation
(AMEX:DOC)
Duska Therapeutics,
Inc.
(OTC:DSKA)
Elan
Corporation
(NYSE: ELN)
Galapagos NV
(Euronext:GLPGA)
Intercell AG
(VSE:ICLL)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Lpath, Inc.
(OTC:LPTN)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware
Information Systems, Inc. (NASDAQ: MEDW)
Pipex Pharmaceuticals,
Inc.
(OTC:PPXP.OB)
Quidel
(NASDAQ:QDEL)
Redpoint Bio Corporation
(OTC:RPBC)
XTLbio
(NASDAQ:XTLB)
VIA Pharmaceuticals,
Inc.
(NASDAQ: VIAP)
ZIOPHARM, INC.
(NASDAQ:ZIOP)
| |
Intercell
AG is a fast growing biotechnology company with a clear strategy and focus
on the design and development of novel vaccines for prevention and treatment
of infectious diseases with substantial unaddressed medical need. The Company's
unique position is based on the combination of antigens and immunizers (adjuvants)
derived from its proprietary technology platforms and its in-house GMP manufacturing
facilities. Intercell's technology has been endorsed by collaborative agreements
with a number of global pharmaceutical companies, including sanofi pasteur,
Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company
has a broad development pipeline with a vaccine for Japanese Encephalitis
undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase
II trials, and five products focused on infectious diseases in the pre-clinical
phase. Intercell is listed on the Vienna stock exchange under the symbol
"ICLL".
COMPANY
NEWS |
COMPANY WEBSITE |
STOCK QUOTE
|